Boehringer Ingelheim

This early-stage trial tests a new drug, BI 764532, in adults with a type of brain tumor (glioma) that has a specific marker called DLL3. The drug is designed to help the body's immune cells attack the tumor. The main goal is to find the highest dose that is safe, and to see if i…

This study tests an experimental medicine called BI 1584862 in 150 adults aged 50 and older with geographic atrophy, a progressive eye disease that causes blind spots. Participants receive either the drug or a placebo for one year, and doctors track changes in the retina using sp…

This study looks at the long-term safety and effectiveness of the drug spesolimab for people with generalized pustular psoriasis (GPP), a rare and severe skin condition. All 131 participants had already taken spesolimab in a previous study. They will receive the drug for up to 5 …

This study tests whether the drug spesolimab can safely and effectively treat repeated flares of generalized pustular psoriasis (GPP), a serious skin condition. Adults with GPP who have had a flare before receive an infusion of spesolimab at the start of a new flare, with a possi…

This early-stage study tests a new experimental drug (BI 770371) alone or with another drug (ezabenlimab) in adults with advanced solid tumors who have no other treatment options. The main goal is to find a safe dose and check for side effects. Participants receive infusions ever…

This study tests a new medicine, BI 771716, against an existing treatment (pegcetacoplan) for geographic atrophy, a progressive eye disease that causes vision loss. About 202 adults aged 50 and older will receive eye injections every 4 weeks for just over a year. The goal is to s…

This early-stage study tests a new daily pill, zongertinib, for people with advanced solid tumors (including lung cancer) that have HER2 gene changes. The first part finds the best dose, and the second part checks if the drug can shrink tumors. Participants stay on treatment as l…

This study tests a new immunotherapy (a protein and virus combo) plus ezabenlimab in adults with advanced pancreatic cancer. The goal is to find a safe dose and see if the combination helps people live longer. Participants are split into two groups: one gets the new treatment, th…

This study tests a new weight-loss medicine called survodutide in over 5,500 adults with obesity or overweight who also have heart or kidney disease or related health problems. Participants receive weekly injections of survodutide or a placebo for up to 2 years and 3 months, alon…

This study tests a new drug, BI 764532, combined with chemotherapy in adults with advanced small cell lung cancer that returned after prior treatment. The goal is to find the safest dose and see if the combination can help control the cancer. Participants continue treatment as lo…

This study tests a new medicine called BI 3032950 in 45 adults with moderate to severe ulcerative colitis who haven't improved with other treatments. The medicine is given first as an IV infusion every 4 weeks, then as a shot under the skin for up to 2 years. Doctors check if sym…

This study tests whether combining three different medicines can shrink tumors in adults with head and neck cancer that has spread or come back. Participants are randomly assigned to receive different combinations of the study drugs as infusions. The goal is to see if these combi…

This early-stage study tests a new medicine called BI 3000202 in 16 adults with rare immune disorders like Aicardi-Goutières syndrome. Participants take the drug as tablets for 40 weeks to see if it is safe and how the body processes it. The goal is to control the disease, not cu…

This study tests a new medicine called BI 764524 for people with moderate to severe diabetic retinopathy, a diabetes-related eye disease. About 188 adults will receive different numbers of eye injections over a year, and doctors will compare their eye health to those getting a sh…

This study was designed to track the safety and effectiveness of spesolimab in Korean adults experiencing flares of generalized pustular psoriasis (GPP), a severe skin condition. The plan was to observe patients receiving the drug in routine medical practice, focusing on side eff…

This early-phase trial tests a new drug combination (obrixtamig plus ezabenlimab) in adults with advanced small cell lung cancer or other neuroendocrine tumors that have not responded to standard treatments. The goal is to find the highest safe dose and see if the drugs can help …

This study looks at whether the medicine BI 1291583 can safely help control bronchiectasis, a long-term lung condition that causes inflammation and infections. About 268 adults who were in earlier studies will take a low, medium, or high dose daily for up to a year. Researchers w…

This early-phase study tests a new experimental drug, BI 765179, in adults with advanced solid tumors or head and neck cancer. The first part finds the safest dose when given alone or with another drug (ezabenlimab). The second part checks if combining BI 765179 with pembrolizuma…

This study tests a new medicine called survodutide to see if it helps people with obesity burn more energy and fat. About 64 adults aged 18 to 65 with a BMI between 30 and 45 will take part. They will receive either survodutide or the existing drug semaglutide once a week for sev…

This early-phase study tests a new daily pill, BI 1823911, in adults with advanced solid tumors (like lung, colorectal, pancreatic, or bile duct cancer) that have a specific KRAS G12C mutation and have stopped responding to other treatments. The study aims to find the safest dose…

This early-phase study tests a new experimental drug, BI 1831169, in adults with advanced solid tumors that have spread or come back. The drug is given alone or with an immunotherapy (anti-PD-1 antibody) to find the safest dose and see if it can shrink tumors. About 190 participa…

This early-phase study tests a new experimental drug, BI 1701963, that blocks a cancer-driving protein called KRAS. It is given alone or with an approved drug, trametinib, to adults with advanced solid tumors that have a KRAS mutation and have stopped responding to standard treat…

This study tests whether combining several drugs can shrink tumors in adults with head and neck cancer that has returned or spread, and where prior treatments have failed. Participants receive a mix of antibodies that boost the immune system, block tumor growth signals, and cut o…

This early-stage trial tests a new experimental drug called BI 764532 (obrixtamig) combined with standard chemotherapy and immunotherapy for adults with extensive-stage small cell lung cancer. The main goal is to find the highest safe dose of the new drug. Participants receive al…

This study looks at the long-term safety of brigimadlin, an experimental cancer drug, in adults with solid tumors who have already taken it for at least 4 cycles. Participants take brigimadlin tablets once every 3 weeks at the study site. Doctors monitor their health, track side …

This study tests a new daily pill, zongertinib, against standard chemotherapy for people with advanced non-small cell lung cancer that has a specific HER2 gene change. About 428 adults who have not had prior treatment for advanced disease will be randomly assigned to receive eith…

This study monitors over 1,000 Japanese patients with chronic kidney disease who take JARDIANCE® tablets daily for a long time. Researchers are checking for side effects and whether the drug helps slow kidney disease progression. The goal is to see how well the medicine works in …

This study follows 2,000 people with systemic sclerosis-associated interstitial lung disease (SSc-ILD) who are taking nintedanib. Researchers want to see how the drug affects lung function, quality of life, and survival over time. Participants are already part of the EUSTAR regis…

This study tests an experimental medicine called BI 1356225 to see if it can help people with opioid use disorder control their impulses. About 60 adults aged 18 to 65 who are already taking buprenorphine for opioid addiction will be randomly assigned to receive either the study …

This study tests a smartphone app called CT-155 for people with schizophrenia who have negative symptoms like low motivation and lack of pleasure. About 262 adults will use the app for 16 weeks, with an option to continue for another 16 weeks, while continuing their usual treatme…

This study tests if two different ways of giving survodutide—a pre-filled syringe and a pre-filled pen—deliver the drug into the body in the same way. About 56 healthy or overweight adults will receive a single dose of each method and have their blood levels measured. The goal is…

This study looks at how different levels of liver disease affect the way the body handles a new medicine called BI 1584862. About 43 adults, some with mild to severe liver problems and some with healthy livers, will take a single dose of the drug. Researchers will check safety an…

This study follows 5 people with cystic fibrosis who previously received a single dose of BI 3720931 gene therapy or placebo. No new treatment is given. Researchers will check for long-term side effects and track lung function over up to 15 years to see if the therapy remains eff…

This study monitors the long-term safety of the drug Ofev in people with systemic scleroderma-associated interstitial lung disease (SSc-ILD) in Japan. It does not test a new treatment but instead collects real-world data on side effects, especially stomach issues like diarrhea an…

This study observes over 547,000 people in France who started taking SGLT2i drugs for type 2 diabetes. Researchers will describe patient characteristics and how the drugs are prescribed, and track heart, kidney, and safety events. The goal is to understand real-world use and outc…

This early-phase study involves 14 adults with advanced head and neck, lung, or skin cancer who have not responded to prior treatments. Researchers use PET/CT scans to see how two experimental antibodies, BI 765063 and BI 770371, travel to tumors when given alongside another immu…

This study looks back at medical records of nearly 8,000 people with HER2-altered metastatic breast cancer in the United States. The goal is to understand how these patients are treated in everyday practice and how long they live. No new treatments are tested; instead, researcher…

This study looks at whether the diabetes drug empagliflozin is as safe and effective in everyday patients as it was in earlier clinical trials. Researchers will analyze health records from over 200,000 adults with type 2 diabetes who started taking empagliflozin or a similar drug…

This study uses health records from 15,000 people with chronic kidney disease in Japan to see if SGLT2 inhibitors (a type of diabetes medicine) are linked to a lower risk of developing anemia. Researchers will also track changes in anemia treatments and costs over time. The goal …

This study follows 157 adults with pulmonary fibrosis who are taking nintedanib and taking part in a special support program in Spain. Researchers will measure how satisfied patients are with the program, and track their quality of life, mood, and symptoms over 12 months. The goa…

This study collects blood samples from 102 people with non-small cell lung cancer, colorectal cancer, or pancreatic cancer to track genetic changes in tumor DNA over time. Participants continue their standard treatments while researchers measure how cancer DNA levels in the blood…

This study tests a new version of the medicine survodutide, which is being developed for obesity and liver conditions. About 100 healthy adults aged 18 to 65 with a BMI between 27 and 40 will receive weekly injections of either the current or new formulation for 28 weeks. Researc…